Vilin Bio Med (NSE:VILINBIO) Debt-to-EBITDA : 1.85 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Vilin Bio Med Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vilin Bio Med's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹52.72 Mil. Vilin Bio Med's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹2.53 Mil. Vilin Bio Med's annualized EBITDA for the quarter that ended in Sep. 2023 was ₹29.94 Mil. Vilin Bio Med's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 1.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vilin Bio Med's Debt-to-EBITDA or its related term are showing as below:

NSE:VILINBIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.69 Med: 6.62 Max: 6.98
Current: 3.69

During the past 3 years, the highest Debt-to-EBITDA Ratio of Vilin Bio Med was 6.98. The lowest was 3.69. And the median was 6.62.

NSE:VILINBIO's Debt-to-EBITDA is ranked worse than
71.17% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs NSE:VILINBIO: 3.69

Vilin Bio Med Debt-to-EBITDA Historical Data

The historical data trend for Vilin Bio Med's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilin Bio Med Debt-to-EBITDA Chart

Vilin Bio Med Annual Data

Trend

Mar20

Mar21

Mar22

Debt-to-EBITDA

5.12

6.62

6.98

Vilin Bio Med Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Sep23
Debt-to-EBITDA	N/A	N/A	N/A	-	1.85

Competitive Comparison of Vilin Bio Med's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vilin Bio Med's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vilin Bio Med's Debt-to-EBITDA falls into.

Vilin Bio Med Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vilin Bio Med's Debt-to-EBITDA for the fiscal year that ended in Mar. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(45.656	+	7.34)	/	7.59
	=	6.98

Vilin Bio Med's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(52.717	+	2.525)	/	29.94
	=	1.85

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Vilin Bio Med (NSE:VILINBIO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Vilin Bio Med Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vilin Bio Med's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Vilin Bio Med (NSE:VILINBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vilin Bio Med Ltd (NSE:VILINBIO) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Opposite Sub Registrar’s Office, Survey No.115/GF/J, Hanumanji Colony, Bowempally, Secunderabad, TG, IND, 500009

Website

http://www.vilinbiomed.co.in

Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules & Nutritional Food supplements.

Vilin Bio Med (NSE:VILINBIO) Headlines

No Headlines